Cargando…

Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies

BACKGROUND: Cardiovascular disease is a primary cause of death in patients with chronic obstructive pulmonary disease (COPD). Beta-blockers have been proved to reduce morbidity and improve survival in patients with cardiac diseases. But the effects of beta-blockers on outcomes in patients with COPD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Qingxia, Sun, Yongchang, Ding, Ning, Lu, Lijin, Chen, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245088/ https://www.ncbi.nlm.nih.gov/pubmed/25427000 http://dx.doi.org/10.1371/journal.pone.0113048

Ejemplares similares

Beta-blocker use and COPD mortality: a systematic review and meta-analysis
por: Etminan, Mahyar, et al.
Publicado: (2012)

Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD
por: Huang, Yueh Lan, et al.
Publicado: (2017)

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)
por: Duffy, Sean, et al.
Publicado: (2017)

Beta-blocker under-use in COPD patients
por: Lim, Kuan Pin, et al.
Publicado: (2017)

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
por: Cotton, Seonaidh, et al.
Publicado: (2022)

β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial
por: Chang, Catherina L., et al.
Publicado: (2017)

Effectiveness of Telemonitoring for Reducing Exacerbation Occurrence in COPD Patients With Past Exacerbation History: A Systematic Review and Meta-Analysis
por: Lu, Jing-wen, et al.
Publicado: (2021)

Who's Afraid of the Big Bad Wolf? Safety of Beta-Blockers in COPD
por: Ambrosio, Giuseppe, et al.
Publicado: (2019)

Effect of β-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study
por: Karimi, Leila, et al.
Publicado: (2021)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison
por: Gulea, Claudia, et al.
Publicado: (2021)

Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients
por: Lu, Hua, et al.
Publicado: (2015)

1297. Azithromycin vs Beta Lactams in Acute Exacerbations of COPD
por: Kale-Pradhan, Pramodini, et al.
Publicado: (2021)

Calcium channel blockers and beta-blockers could increased mortality of patients with COVID-19
por: Esteban-Lucia, L, et al.
Publicado: (2021)

Hypogammaglobulinemia and Risk of Exacerbation and Mortality in Patients with COPD
por: Holm, Are M, et al.
Publicado: (2020)

Cardiovascular predictors of mortality and exacerbations in patients with COPD
por: Alter, Peter, et al.
Publicado: (2022)

90-day mortality of severe sepsis and septic shock is reduced by initiation of oral beta-blocker therapy and increased by discontinuation of a pre-existing beta-blocker treatment
por: Fuchs, C, et al.
Publicado: (2015)

Beta-blockers reduce intestinal permeability and early mortality following traumatic brain injury in Drosophila
por: Scharenbrock, Amanda R, et al.
Publicado: (2021)

Sensitivity of Lung Resistance and Compliance to Beta-Blocker Induced Bronchoconstriction and Long Acting Beta-Agonist Withdrawal in COPD
por: Jabbal, Sunny, et al.
Publicado: (2017)

Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD
por: van Gestel, Yvette RBM, et al.
Publicado: (2009)

Neutrophil-to-Lymphocyte Ratio Predicts Clinical Outcome of Severe Acute Exacerbation of COPD in Frequent Exacerbators
por: Lu, Fang-Ying, et al.
Publicado: (2021)

β‐Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study
por: Andell, Pontus, et al.
Publicado: (2015)

Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD
por: Baalbaki, Nour, et al.
Publicado: (2022)

The effect of beta-blockers on mortality in patients with heart failure and atrial fibrillation: A meta-analysis of observational cohort and randomized controlled studies
por: Ma, Gai-gai, et al.
Publicado: (2020)

Beta-blocker and survival in patients with lung cancer: A meta-analysis
por: Lei, Zhen, et al.
Publicado: (2021)

Exacerbations of COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Exacerbations of COPD
por: Viniol, Christian, et al.
Publicado: (2018)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Thiazolidinediones are associated with a reduced risk of COPD exacerbations
por: Rinne, Seppo T, et al.
Publicado: (2015)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
por: Du, Qingxia, et al.
Publicado: (2016)

Beta-blockers reduce severe exacerbation in patients with mild chronic obstructive pulmonary disease with atrial fibrillation: a population-based cohort study
por: Lin, Shan-Ju, et al.
Publicado: (2023)

Impact of statins and ACE inhibitors on mortality after COPD exacerbations
por: Mortensen, Eric M, et al.
Publicado: (2009)

One-year mortality after severe COPD exacerbation in Bulgaria
por: Mekov, Evgeni, et al.
Publicado: (2016)

Predictors of one-year mortality after hospitalization for an exacerbation of COPD
por: Esteban, Cristóbal, et al.
Publicado: (2018)

Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD
por: Lonergan, Mike, et al.
Publicado: (2020)

Employment Status, Readmission and Mortality After Acute Exacerbation of COPD
por: Jacobsen, Peter Ascanius, et al.
Publicado: (2021)

Real-World Effectiveness of Beta-Blockers versus Other Antihypertensives in Reducing All-Cause Mortality and Cardiovascular Events
por: Foch, Caroline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ocbsv9lbj6epm74rv8in96046